▶ 調査レポート

咳過敏症候群治療の世界市場:市場規模、シェア、成長、動向、予測

• 英文タイトル:Cough Hypersensitivity Syndrome Treatment Market (Drug Class: Antitussive Agents, Inhaled Corticosteroids, Short Acting Beta-2 Agonists, Anti-cholinergics, Antihistamines, Proton Pump Inhibitors, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。咳過敏症候群治療の世界市場:市場規模、シェア、成長、動向、予測 / Cough Hypersensitivity Syndrome Treatment Market (Drug Class: Antitussive Agents, Inhaled Corticosteroids, Short Acting Beta-2 Agonists, Anti-cholinergics, Antihistamines, Proton Pump Inhibitors, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TPM-NV148資料のイメージです。• レポートコード:TPM-NV148
• 出版社/出版日:Transparency Market Research / 2019年11月8日
• レポート形態:英文、PDF、167ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥625,860 (USD5,795)▷ お問い合わせ
  Multi User¥949,860 (USD8,795)▷ お問い合わせ
  Global Site License¥1,273,860 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、咳過敏症候群治療の世界市場について調べ、咳過敏症候群治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別(鎮咳薬、吸入コルチコステロイド、短時間作用型ベータ2アゴニスト、抗コリン薬、抗ヒスタミン薬、プロトンポンプ阻害薬、その他)分析、流通チャンネル別(病院薬局、小売薬局、オンライン薬局)分析、関連企業情報などをまとめました。
・咳過敏症候群治療の市場概要
・咳過敏症候群治療の市場動向
・咳過敏症候群治療の世界市場規模・予測
・咳過敏症候群治療市場:薬物クラス別(鎮咳薬、吸入コルチコステロイド、短時間作用型ベータ2アゴニスト、抗コリン薬、抗ヒスタミン薬、プロトンポンプ阻害薬、その他)
・咳過敏症候群治療市場:流通チャンネル別(病院薬局、小売薬局、オンライン薬局)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

On a global level, the alarming prevalence of chronic cough amongst individuals has propelled healthcare companies in the cough hypersensitivity syndrome treatment market to develop efficacious treatment options. As such, they are increasing their focus on developing improved formulations of antitussive agents. This trend is distinctly true, since antitussive agents are projected to dominate the cough hypersensitivity syndrome treatment market, with an estimated revenue of ~US$ 2.8 billion by 2027.

In order to relieve patients from cough hypersensitivity, healthcare companies are investing in opiates and GABA (gamma-aminobutyric acid)-related compounds. Opiates serve as effective cough suppressants and possess efficacious antitussive properties to treat chronic intractable cough. Likewise, companies are increasing their production capabilities of tramadol, an opioid medication that is similar to the molecular formula of codeine drugs.

Since chronic cough causes increased body pain, companies in the cough hypersensitivity syndrome treatment market are increasing the availability of babapentin and pregabalin, which are GABA-related compounds, and act as neuromodulators for the treatment of neuropathic pain and epilepsy. It has been found in placebo-controlled trials that, gabapentin is well-tolerated for the treatment of refractory chronic cough.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cough Hypersensitivity Syndrome Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Respiratory Drug Classes Definition

4.1.2. Industry Evolution/Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

4.5. Porter’s Five Force Analysis

5. Key Insights

5.1. Epidemiology Cough hypersensitivity syndrome

5.2. Pipeline Analysis

6. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Drug Class, 2017–2027

6.3.1. Antitussive Agents

6.3.2. Inhaled Corticosteroids (ICS)

6.3.3. Short Acting Beta2-Agonists (SABA)

6.3.4. Anti-cholinergics

6.3.5. Antihistamines

6.3.6. Proton Pump Inhibitors

6.3.7. Others

6.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Drug Class

7. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Distribution Channel

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

7.3.1. Hospital Pharmacies

7.3.2. Retail Pharmacies

7.3.3. Online Pharmacies

7.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel

8. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Region

8.1. Key Findings

8.2. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Region

9. North America Cough Hypersensitivity Syndrome Treatment Market Value Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

9.2.1. Antitussive Agents

9.2.2. Inhaled Corticosteroids (ICS)

9.2.3. Short Acting Beta2-Agonists (SABA)

9.2.4. Anti-cholinergics

9.2.5. Antihistamines

9.2.6. Proton Pump Inhibitors

9.2.7. Others

9.3. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. North America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis

9.5.1. By Drug Class

9.5.2. By Distribution Channel

9.5.3. By Country

10. Europe Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

10.2.1. Antitussive Agents

10.2.2. Inhaled corticosteroids (ICS)

10.2.3. Short-Acting Beta2-Agonists (SABA)

10.2.4. Anti-cholinergics

10.2.5. Antihistamines

10.2.6. Proton Pump Inhibitors

10.2.7. Others

10.3. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.4. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis

10.5.1. By Drug Class

10.5.2. By Distribution Channel

10.5.3. By Country

11. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

11.2.1. Antitussive Agents

11.2.2. Inhaled corticosteroids (ICS)

11.2.3. Short-Acting Beta2-Agonists (SABA)

11.2.4. Anti-cholinergics

11.2.5. Antihistamines

11.2.6. Proton Pump Inhibitors

11.2.7. Others

11.3. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.4. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis

11.5.1. By Drug Class

11.5.2. By Distribution Channel

11.5.3. By Country/Sub-region

12. Latin America Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

12.2.1. Antitussive Agents

12.2.2. Inhaled corticosteroids (ICS)

12.2.3. Short-Acting Beta2-Agonists (SABA)

12.2.4. Anti-cholinergics

12.2.5. Antihistamines

12.2.6. Proton Pump Inhibitors

12.2.7. Others

12.3. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.4. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis

12.5.1. By Drug Class

12.5.2. By Distribution Channel

12.5.3. By Country/Sub-region

13. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

13.2.1. Antitussive Agents

13.2.2. Inhaled corticosteroids (ICS)

13.2.3. Short-Acting Beta2-Agonists (SABA)

13.2.4. Anti-cholinergics

13.2.5. Antihistamines

13.2.6. Proton Pump Inhibitors

13.2.7. Others

13.3. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.4. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027

13.4.1. GCC

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis

13.5.1. By Drug Class

13.5.2. By Distribution Channel

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player – Competition Matrix (By Tier and Size of companies)

14.2. Market Share Analysis by Company (2018)

14.3. Company Profiles

14.3.1. Pfizer, Inc.

14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.1.2. Financial Overview

14.3.1.3. Product Portfolio

14.3.1.4. Strategic Overview

14.3.1.5. SWOT Analysis

14.3.2. GlaxoSmithKline plc

14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.2.2. Financial Overview

14.3.2.3. Product Portfolio

14.3.2.4. Strategic Overview

14.3.2.5. SWOT Analysis

14.3.3. Boehringer Ingelheim GmbH

14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.3.2. Financial Overview

14.3.3.3. Product Portfolio

14.3.3.4. Strategic Overview

14.3.3.5. SWOT Analysis

14.3.4. AstraZeneca

14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.4.2. Financial Overview

14.3.4.3. Product Portfolio

14.3.4.4. Strategic Overview

14.3.4.5. SWOT Analysis

14.3.5. F. Hoffmann-La Roche Ltd.

14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.5.2. Financial Overview

14.3.5.3. Product Portfolio

14.3.5.4. Strategic Overview

14.3.5.5. SWOT Analysis

14.3.6. Teva Pharmaceutical Industries Ltd.

14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.6.2. Financial Overview

14.3.6.3. Product Portfolio

14.3.6.4. Strategic Overview

14.3.6.5. SWOT Analysis

14.3.7. Novartis AG

14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.7.2. Financial Overview

14.3.7.3. Product Portfolio

14.3.7.4. Strategic Overview

14.3.7.5. SWOT Analysis

14.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.8.2. Financial Overview

14.3.8.3. Product Portfolio

14.3.8.4. Strategic Overview

14.3.8.5. SWOT Analysis

14.3.9. Vertex Pharmaceuticals Incorporated

14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.9.2. Financial Overview

14.3.9.3. Product Portfolio

14.3.9.4. Strategic Overview

14.3.9.5. SWOT Analysis

14.3.10. Johnson & Johnson Consumer Inc.

14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.10.2. Financial Overview

14.3.10.3. Product Portfolio

14.3.10.4. Strategic Overview

14.3.10.5. SWOT Analysis